QUAZAR AML-001: Evaluating CC-486 as a maintenance therapy for older patients with acute myeloid leukaemia in first remission

Bookmark and Share
Published: 10 Dec 2019
Views: 494
Rating:
Save
Prof Andrew Wei - Monash University, Melbourne, Australia

Prof Andrew Wei presents at ASH 2019, the primary findings from the QUAZAR AML-001 maintenance trial, which evaluated CC-486, an oral formulation of azacitidine as a maintenance therapy in older patients with acute myeloid leukaemia (AML) in first remission following intensive induction chemotherapy.

Watch our interview with Prof Wei here

Read more about the study here